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Changes in the Utilization of Osteoporosis Drugs after the 2010 FDA
Bisphosphonate Drug Safety Communication
Abstract
INTRODUCTION: In October 2010, the US Food and Drug Administration (FDA)
issued a safety communication regarding the risks of atypical fractures of the femur, with
bisphosphonates drugs. This study evaluated the impact of the bisphosphonates FDA
safety communication on the utilization of osteoporosis medications in Medicaid
programs.
METHODS: Osteoporosis drugs utilization data from the July 2006 to June 2014 were
extracted from the national Summary Files from the Medicaid State Drug Utilization
Data maintained by the Centers for Medicare & Medicaid Services (CMS). We
performed an interrupted time series analyses to evaluate trends in utilization of
osteoporosis drugs before and after the 2010 FDA safety commination.
RESULTS: Time-series analyses of osteoporosis drug utilization in Medicaid program
revealed a significant downward trend associated with the 2010 FDA bisphosphonates
safety communication. Before the FDA safety communication was issued, the utilization
rate was slightly decreased between 2006 and 2010. In the year following the FDA safety
communication the bisphosphonate DDDs per 1000 beneficiaries of fell 22% yearly until
the end of study period.
CONCLUSIONS: The 2010 FDA bisphosphonates safety communication appeared to
have influenced Osteoporosis utilization in Medicaid recipients. The 2010 FDA
bisphosphonates safety communication was associated with a significant reduction in the
utilization of bisphosphonates in the Medicaid program.

KEY WORDS: Medicaid; osteoporosis; bisphosphonate; US Food and Drug
Admiration; regulatory warning; Utilization.

Introduction

Bisphosphonates are currently considered the first-line therapy for the prevention
and treatment of osteoporosis. In the United States (US), 14.7 million prescriptions of
oral bisphosphonates were dispensed in 2012.1 Alendronate was the first bisphosphonate
to obtain FDA approval for the treatment and prevention of osteoporosis, followed by the
approval of several bisphosphonates with different efficacies and dosing regimens. 2,3
Several studies indicated the association between the long-term use of
bisphosphonates and the risk of atypical fracture of the femur. 4-6 The FDA reviewed these
data and issued a Drug Safety Communication (DSC) in 2010 regarding the risk of
atypical femur fractures associated with the long-term used of bisphosphonates. The FDA
required drug manufacturers to include a limitation of use statement, “The optimal
duration of use has not been determined. For patients at low-risk for fracture, consider
drug discontinuation after 3 to 5 years of use,” on the label of all bisphosphonates
approved for the treatment of osteoporosis. 7 In addition, a medication guide should be
given to the patient with each bisphosphonate prescription describing the risk and
symptoms of these fractures.7 The labeling changes and medication guide affected several
brands of bisphosphonates approved for osteoporosis and their generic products (e.g.,
alendronate, alendronate and cholecalciferol, risedronate, risedronate delayed release,
ibandronate, zoledronic acid).7
Despite the high prevalence and economic burden of osteoporosis, the literature
on the utilization and spending on osteoporosis drugs is scarce.8,9 Furthermore, no
empirical studies have been conducted assessing trends in the utilization and spending on
osteoporosis drugs and the changes in the patterns of bisphosphonate utilization in the

Medicaid program following the DSC are unknown. In an attempt to understand how the
FDA safety recommendation actions affected prescribing practices, we investigated the
utilization of bisphosphonates before and after FDA regulatory actions in the Medicaid
program from July 2006 through June 2014.
Material and Methods

Data Sources
The primary data source is the National Summary Files from the Medicaid State
Drug Utilization Data maintained by the Centers for Medicare and Medicaid Services
(CMS). The data are fee-for-service pharmacy claim records for outpatient drugs
dispensed. This data set is available for 49 states (except Arizona) and the District of
Colombia; it includes only outpatient pharmacy prescriptions reimbursed by Medicaid in
the period July 2006 through June 2014.10
Each data record of this dataset includes: drug name, national drug code (NDC),
units reimbursed, number of prescriptions, and total pharmacy reimbursement amount
including drug cost and dispensing fees. An updated list of osteoporosis drugs marketed
in the US was obtained from the U.S. Food and Drug Administration (FDA) online
databases. All osteoporosis drugs were identified by their national drug codes (NDCs)
using the FDA NDC directory.11

Information on missing NDCs in the FDA NDC

directory was compiled from Physicians' Desk Reference (PDR).
The FDA regulatory data and the Medicaid state drug utilization data for each
osteoporosis drug were merged to create a unique dataset that contained FDA regulatory
data and Medicaid utilization using the NDC and drug name.

Data Analysis
Drug utilization was measured by the total defined daily doses (DDDs). All drug
units (e.g., tablets, nasal spray, injections) were converted to DDDs using the World
Health Organization Anatomical Therapeutic Chemical/Defined Daily Dose (WHO
ATC/DDD) index.12 When the DDD was not available, the daily dose was calculated
using the FDA labeling information for drugs which is available on the FDA website.
This method allows for a comparison of the utilization and spending of different
osteoporosis drug classes using a standardized unit.
We conducted an interrupted time series analysis (ITS) to assess the association of
the 2010 FDA DSC on the utilization of bisphosphonates in the Medicaid program. 13-15
Interrupted time design is one of the strongest quasi-experimental designs to assess the
longitudinal effects of an intervention. 16.17
Autoregressive integrated moving average (ARIMA) techniques are well
established in the literature to perform a time series analysis.18-22 In contrast with other
techniques like a simple pre- and post-intervention means test which results in
overestimation or underestimation of effect, ARIMA modeling takes into account secular
trends and it only requires data of the variables of interest for the analysis. Additionally
ARIMA is more flexible than other techniques in fitting the data. 22-24
Osteoporosis drug utilization and pharmacy reimbursement were calculated per
1,000 Medicaid beneficiaries to account for changes over time in the number of Medicaid
beneficiaries. The time series ARIMA model also controlled for the demographic
changes in the Medicaid population adjusting for the proportion of women 65 years and
over.

A stepwise approach was used to select the best fit model by adding different
parameters to the model such as availability of competitors’ drugs, introduction of new
drugs and generic entry.. Akaike Information Criteria (AIC) were used to select the best
fitting model. Statistical significance was set at 0.05 (two-sided). All statistical analyses
were performed using SAS software, version 9.4 for Windows (SAS Institute, Inc., Cary,
NC, USA).
Results

Five drug classes were used in this study (Table 1). Hormonal replacement
therapies (HRTs) are indicated for treatment of multiple diseases and were excluded from
analysis because it was not possible to differentiate what percentage of the utilization of
HRTs was used for each disease. The following HRTs were excluded from analysis:
estropipate (approved in 1986), conjugated estrogens (1986), estradiol (1994), conjugated
estrogens and medroxyprogesterone acetate (1995), estradiol and norethindrone acetate
(1998), ethinyl estradiol and norethindrone acetate (1999), estradiol and norgestimate
(1999), estradiol and levonorgestrel (2006), and bazedoxifene acetate and conjugated
estrogens (2013).
During the study period, bisphosphonates was the therapeutic subclass with the
highest percentage of utilization (Table 2) and also represented the highest market share
among other osteoporosis drugs (Figure 1). The utilization of bisphosphonates increased
since the approval of alendronate. In the beginning of the study period third quarter of
2006, the utilization of bisphosphonates was 252.6 DDDs per 1000 beneficiaries. The

trends in bisphosphonate utilization in the Medicaid program decreased by 3% annually
and reached 218.7 DDDs per 1000 beneficiaries at the end of 2010.
The first-order autoregressive model was selected as the best fit model using
AIC. Finding from the ARIMA model indicated a significant decrease in the utilization of
bisphosphonates following the issue of the DSC in October 2010 (p<0.001) (Table 3).
The DSC resulted in a decrease of 31 DDDs per 1000 beneficiaries per quarter in
Medicaid bisphosphonate utilization (95% CI: -14.65 to -52.5, p=0.001).

No such trends were observed for other osteoporosis drugs such as SERMs,
teriparatide and calcitonins. The utilization of SERMs decreased from 19.62 DDDs per
1000 beneficiaries in the third quarters of 2006 to 15.77 DDDs per 1000 beneficiaries
followed by a decreased in the fourth quarter of 2011 however the trends were not
statistically significant (p=0.33).

For SERM, although we can see a decline after the 2010 FDA DSC, there is no
statistically significant effect on utilization of SERM after fitting this into ARIMA model
(Table 3). Calcitonins had a steady decrease in its utilization at a rate of 5.2% per quarter
from 4.4 DDDs per 1000 beneficiaries to 0.71 DDDs per 1000 beneficiaries at the end of
study period, and the utilization of teriparatide was shown to decrease by 0.0846 each
quarter until the second quarter of 2014. The reduction of calcitonins and teriparatide
were not associated with the 2010 FDA DSC (p=0.655, p=0.293) (Figure 2).

Denosumab entered the market as a first-line therapy for patients with severe
osteoporosis in June 1, 2010. The utilization of denosumab was 0.04 DDDs per 1000 and
increased at a rate of 27% and reached 20.2039 DDDs per 1000 by June 2014. However,

our model indicated that the increase in the utilization of denosumab during the post FDA
warning period was not statistically significant (p value= 0.751). This means that the
DSC did not affect the utilization of this drug. Among bisphosphonate drugs, alendronate
was associated with the highest utilization by Medicaid recipients. All branded and
generic bisphosphonates drugs were affected by the 2010 DSC (Figure 3).
Discussion

During the last twenty years, the FDA approved several osteoporosis drugs from
five different therapeutic subclasses. In January 1995, only one osteoporosis drug (other
than HRTs and calcitonin) was available in the US market. By the end of 2014, the FDA
had approved 9 single active ingredients and 2 fixed dose combination drugs.
Study findings reveal a significant change in the pattern of osteoporosis drugs.
During the period between 2006 and before the FDA issued the DSC in 2010, we
observed a decrease in the utilization of bisphosphonates and other osteoporosis drugs.
Previous studies on the use of bisphosphonates observed a significantly decrease in the
use of bisphosphonates in the US in patients under 45 years, 25 and a decrease in overall
osteoporosis drugs post-fragility fracture.26
The safety of bisphosphonate drugs has been addressed in several studies which
indicate an association between the long-term use of bisphosphonates and the risk of a
atrial fibrillation,27 severe musculoskeletal pain,28,29 typical fracture of the femur4-6 and
esophageal cancer.30 The FDA has investigated these risks and issued several DSCs on
the use of bisphosphonates in the treatment and prevention of osteoporosis. 31-33 The FDA
did not conclude that taking bisphosphonates increases the risk of atrial fibrillation or
esophageal cancer. However, the FDA issued a warning regarding atypical fractures with

the long-term used of bisphosphonates. As a result, the FDA required substantial changes
in bisphosphonate labels.
In the case of alendronate, the FDA approved a total of 33 supplements including
2 new or modified indications and 22 labeling revisions in the period 2000-April 2014.
Alendronate labeling safety revisions were related to the following: gastrointestinal
warnings (2002);

scleritis and symptomatic hypocalcemia post-marketing adverse

reports, and severe skin adverse post-marketing adverse reports (2003); theoretical risk of
fetal harm (2004); episcleritis post-marketing adverse reports and osteonecrosis of the
jaw precautions (2005); asthenia, dizziness, joint swelling, peripheral edema, and vertigo
post-marketing adverse reports (2006); musculoskeletal pain precautions and alopecia
post-marketing adverse reports (2008), low-energy femoral shaft and subtrochanteric
fractures post-marketing adverse reports, osteonecrosis of the jaw precautions and postmarketing adverse reports, and revision of the warnings related to gastrointestinal adverse
events associated with the use of bisphosphonates (2010); and osteonecrosis of the jaw
warnings and precautions, and asthma exacerbations post-marketing adverse reports
(2013). Additionally, the FDA required a risk evaluation and mitigation strategy (REMS)
with information pertains to the risk of atypical subtrochanteric and diaphyseal femoral
fractures with the bisphosphonate drug class in 2010. The FDA decided in 2011 that the
REMS for alendronate were no longer required.
In spite of the number of safety label changes, the utilization of alendronate did
not significantly change until the 2010 warnings, precautions and REMS. Given that
safety actions including warnings, precautions and post-marketing adverse reports
released by the FDA before 2010 did not significantly change the use of bisphosphonates,

we hypothesized that the changes in utilization observed after 2010 were related to the
implementation of REMS for bisphosphonates that required communications of the risks
to patients before starting the therapy.
The 2010 DSC was associated with a significant change in the pattern of
utilization of osteoporosis drugs. Although there was an overall decline in the utilization
of osteoporosis drugs, our findings indicated that the 2010 DSC only significantly
affected the utilization of bisphosphonates. Our regression model points to a delayed
effect of the DSC on the utilization of SERMs, as a sharp decline in the utilization of
SERMs in Medicaid began in the fourth quarter of 2011, a year after the DSC was
released by the FDA. This reduction in SERMs may be due to factors not assessed in this
study.
We also noted that the decrease in the utilization of bisphosphonates was
associated with an increase in denosumab use in the same period, but our results
indicated that this increase was not related to the DSC. This increase may be related to
the fact that denosumab is indicated for patients with severe osteoporosis.
The Medicaid population increased during the study period from 33 million in
1995 to 65 million in 2014. The demographic distribution of the Medicaid population
also changed during this study period. While women represented around 59% of the total
Medicaid population during the entire period of analysis, the percentage of the population
aged 65 and older, that are more likely to use osteoporosis drugs, decreased from 12% in
1995 to 8% in 2014.
This study has several limitations. Information about the characteristics of the
Medicaid patient population using osteoporosis drugs is not available for analysis of the

impact of FDA DSC on patient care. Also, the utilization of osteoporosis drugs was
estimated using DDDs. The DDDs do not represent the actual or FDA approved
recommended daily dosages for osteoporosis drugs. Finally, these results relate to the
Medicaid program and may not be generalizable to a broader population.
Conclusions

Time series analyses of osteoporosis drug utilization in the Medicaid program
showed a significant reduction in the use of bisphosphonates following the 2010
bisphosphonate FDA drug safety communication. This drug safety communication
appears to have had a similar effect on other classes of osteoporosis drugs with the
exception of denosumab. However, without clinical data, the appropriateness of the effect
on this regulatory action is uncertain. Further research may evaluate the effect of the
decline in utilization of osteoporosis drugs on fractures.
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Figure 1. Market Share of Osteoporosis Drug Defined Daily Dose in the Medicaid
Fee-For- Service Program (Q3 2006-Q2 2014)
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Figure 2. Impact of the 2010 FDA Bisphosphonates Safety Communication on
the Utilization of Osteoporosis Drugs in the Medicaid Fee-for-Service Program
(DDD per 1000 Beneficiaries)
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Figure 2. (Continued) Impact of the 2010 FDA Bisphosphonates Safety
Communication on the Utilization of Osteoporosis Drugs in the Medicaid Fee-forService Program (DDD per 1000 Beneficiaries)
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Figure 3. Utilization of Brand and Generic Osteoporosis Drugs in the Medicaid FeeFor-Service Program, DDD per 1000 beneficiaries (Q3 2006 – Q2 2014)

Table 1. List of Osteoporosis Drugs Included in the Study
Chemical Subgroup

Active Ingredient(s)

Bisphosphonates

ibandronate sodium

2003

zoledronic acid

2007

alendronate sodium

1995

risedronate sodium

2000

alendronate sodium; cholecalciferol
calcitonin salmon

2005
1995

calcitonin salmon recombinant

2005

Parathyroid
hormones
RANKL inhibitors

teriparatide recombinant human

2002

denosumab

2010

SERM

raloxifene hydrochloride

1997

Calcitonins

FDA Approval
Year

Table 2. Utilization of Osteoporosis Drugs in the Medicaid Fee-For-Service Program (Q3 2006-Q2 2014)

DDDs per 1000 beneficiaries
Year

Total
Utilization

Market Share as Percentage of Total DDD

BP

Teriparatide

Calcitonin

SERM

Denosumab

BP

Teriparatide

Calcitonin

SERM

Denosumab

2006

559.1

506.1

5.89

8.42

38.7

-

90.50%

1.10%

1.50%

6.90%

-

2007

1109.18

1014.35

11.19

15.55

68.09

-

91.50%

1.00%

1.40%

6.10%

-

2008

1027.35

934.47

9.74

16.16

66.98

-

91.00%

0.90%

1.60%

6.50%

-

2009

1005.16

921.89

7.36

13.39

62.51

-

91.70%

0.70%

1.30%

6.20%

-

2010

945.44

865.86

7.45

9.9

61.92

0.31

91.60%

0.80%

1.00%

6.50%

0.00%

2011

567.72

502.72

6.18

7.58

46.86

4.38

88.60%

1.10%

1.30%

8.30%

0.80%

2012

278.41

226.23

3.39

5.8

13

30

81.30%

1.20%

2.10%

4.70%

10.80%

2013

241.93

167.34

2.72

4.07

9.65

58.16

69.20%

1.10%

1.70%

4.00%

24.00%

2014

112.92

73.39

1.17

1.42

3.69

33.25

65.00%

1.00%

1.30%

3.30%

29.40%

Table 3. Impact of the FDA Safety Communication on Bisphosphonate Utilization
Model

Intervention

Adjusted for

ARIMA (1,0,0)

2010_FDA

Women

a

Coefficient

SE

t

b

P value

Aged
Bisphosphonates

-30.948

8.184

-3.781

0.001

Calcitonins

-0.053

.117

-.452

.655

SERM

-1.625

1.516

-1.072

.332

Teriparatide

-0.149

.132

-1.129

.293

*The model was adjusted for percentage of elderly and women in Medicaid program.
a
Coefficient= utilization changed after the intervention take place
b
Statistical significant set at p value <0.05

